{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:28:43Z","timestamp":1790260123427,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":353,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:p>The primary objective of this study was to determine the complete remission (CR) rate achieved with the FLAG (fludarabine phosphate, cytarabine and granulocyte colony\u2010stimulating factor) regimen in patients with relapsed or refractory acute myeloid leukaemia (AML) or <jats:italic>de novo<\/jats:italic> refractory anaemia with excess of blasts in transformation (RAEB\u2010t). Secondary objectives were to evaluate survival and toxicity. Induction treatment consisted of between one and two courses of FLAG. Patients achieving CR received between one and two courses of consolidation treatment. Eighty\u2010three of the 89 patients entering the study were eligible for assessment. CR rates were: 17 out of 21 (81%) in late relapse AML (Group 1), 13 out of 44 (30%) in early relapse\/refractory AML (Group 2), and 10 out of 18 (56%) in <jats:italic>de novo<\/jats:italic> RAEB\u2010t (Group 3). Thirty\u2010four of the 40 responders (85%) achieved CR after one induction course. Median survival times were 1\u00b74\u2003years, 3\u2003months and 1\u00b76\u2003years in Groups 1, 2 and 3 respectively. Other than myelosuppression, the FLAG regimen was not generally associated with clinically significant toxicity and was well tolerated by most patients including the elderly. The FLAG regimen offers a very effective alternative treatment for CR induction in poor prognosis adult patients with either relapsed or refractory AML or <jats:italic>de novo<\/jats:italic> RAEB\u2010t. FLAG delivers high\u2010dose treatment without increasing overall toxicity, an approach which is of particular value in older patients, who constitute the majority in these diseases. It is therefore an important advance in developing new treatment options for these patients.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.02551.x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T10:10:00Z","timestamp":1027678200000},"page":"127-137","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["A multicentre, open, non\u2010comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony\u2010stimulating factor in relapsed and refractory acute myeloid leukaemia and <i>de novo<\/i> refractory anaemia with excess of blasts in transformation"],"prefix":"10.1111","volume":"112","author":[{"given":"G.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J.","family":"Littlewood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Duncombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. B.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. S.","family":"Ganly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. E.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Deane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Brookes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Tollerfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109064874"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.5.1710.1710"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(97)09214-3"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401406"},{"key":"e_1_2_6_6_1","first-page":"513","article-title":"High efficacy of fludarabine\u2010containing therapy (FLAG\u2010FLANG) in poor risk acute myeloid leukemia","volume":"81","author":"Clavio M.","year":"1996","journal-title":"Haematologica"},{"key":"e_1_2_6_7_1","first-page":"1805","article-title":"Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC\u2010LCG)","volume":"9","author":"De Witte T.","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309148532"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.671"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood.V93.8.2478","article-title":"Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +\/\u2013 all\u2010trans retinoic acid +\/\u2013 granulocyte colony\u2010stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome","volume":"93","author":"Estey E.H.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08616.x"},{"key":"e_1_2_6_12_1","first-page":"329","article-title":"Modulation of arabinosyInucleoside metabolism by arabinosylnucleotides in human leukemia cells","volume":"48","author":"Gandhi V.","year":"1988","journal-title":"Cancer Research"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.116"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2322"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/JCO.1989.7.1.45","article-title":"Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate\u2010dose cytarabine","volume":"7","author":"Harousseau J.L.","year":"1989","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050239"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.8.1071"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410063311402"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-8652(199806)58:2<105::aid-ajh3>3.0.co;2-w"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199709068275"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4763281.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050163"},{"key":"e_1_2_6_26_1","first-page":"2076","article-title":"Fludarabine + Ara\u2010C + G\u2010CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells","volume":"8","author":"Tosi P.","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010796"},{"key":"e_1_2_6_28_1","first-page":"1842","article-title":"FLAG (fludarabine + high\u2010dose cytarabine + G\u2010CSF): an effective and tolerable protocol for the treatment of \u2018poor risk\u2019 acute myeloid leukemias","volume":"8","author":"Visani G.","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.2973114.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02551.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02551.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.02551.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T01:33:27Z","timestamp":1697506407000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.02551.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1046\/j.1365-2141.2001.02551.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02551.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]},"assertion":[{"value":"2001-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}